Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 11, 1999, Pages 4278-4282

  Lemieux, Simone ^a   Lewis, Gary F ^a   Ben Chetrit, Avraham ^a   Steiner, George ^a   Greenblatt, Ellen M ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CLINICAL ARTICLE; CORONARY RISK; DISEASE ASSOCIATION; DYSLIPOPROTEINEMIA; FEMALE; FEMALE INFERTILITY; HUMAN; HYPERANDROGENISM; INSULIN SENSITIVITY; LAPAROSCOPIC SURGERY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

FALLOPIA;

EID: 0033323808     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.11.4278     Document Type: Review

References (43)

1. Polycystic ovary syndrome
2. The genetics of polycystic ovary syndrome
3. Polycystic ovary syndrome
4. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome
5. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
6. Insulin resistance in nonobese patients with polycystic ovarian disease
7. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome
8. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women
9. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization
10. Clinical signs of androgen excess as risk factors for coronary artery disease
11. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease
12. Relationship of androgenic activity to body fat topography fat cell morphology, and metabolic aberrations in premenopausal women
13. Relationship of androgenic activity to splanchnic insulin metabolism and peripheral glucose utilization in premenopausal women
14. Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion
15. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome
16. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states
17. The influence of androgens on insulin resistance
18. Insulin resistance improves in hyperandrogenic women treated with Lupron
19. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
20. TroglitazOne improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
21. Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome
22. Surgically induced ovulation in the polycystic ovary syndrome: Wedge resection revisited in the age of laparoscopy
23. Endocrine changes after laparoscopic ovarian cautery in polycystic ovarian syndrome
24. Glucose clamp technique: A method for quantifying insulin secretion and resistance
25. Effects of massive obesity on insulin sensitivity and insulin clearance and the metabolic response to insulin as assessed by the euglycemic clamp technique
26. Effect of time, temperature and freezing on the stability of immunoreactive LH, FSH, TSH, growth hormone, prolactin and insulin in plasma
27. Sur un dosage rapide du cholesterol lie aux α-et aux β-lipoproteines du serum
28. Improved method for quantitation of B apoprotein in plasma lipoproteins by electroimmunoassay
29. Electroimmuno assay
30. Detection and quantitation of LDL subfractions
31. Ovarian electrocauterization causes LH-regulated but not insulin-regulated endocrine changes
32. Lipid Research Clinics Program reference values for hyperlipidemia and hypolipidemia
33. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham Offspring Study
34. Reference intervals for plasma apolipoprotein A-1 determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham Offspring Study
35. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
36. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease
37. The insulin resistance syndrome revisited
38. The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome
39. Surgical options in polycystic ovary syndrome patients who do not respond to medical ovulation induction
40. The effect of laparoscopic multiple punch resection of the ovary on hypothalamo-pituitary axis in polycystic ovary syndrome
41. Endocrine changes and clinical outcome after laparoscopic ovarian resection in women with polycystic ovaries
42. Hormonal response to electrocautery of the ovary in patients with polycystic ovarian disease
43. A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with the polycystic ovary syndrome